SS
ALPN

Steve Schonfeld’s Alpine Immune Sciences Inc ALPN Stock Holding History

Steve Schonfeld’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-90,937
Closed -$1.04M – 2325
2023
Q3 		$1.04M Buy
90,937
+78,037
+605% +$960K 0.01% 1010
2023
Q2 		$133K Buy
+12,900
New +$116K ﹤0.01% 1665

Other funds holding ALPN

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Steve Schonfeld's ALPN Position: Q4 2023 in Review

Steve Schonfeld sold out of Alpine Immune Sciences Inc (ALPN) in Q4 2023, closing a stake of 90,937 shares — an estimated $1.04M sold.

Steve Schonfeld first reported a position in ALPN in Q2 2023 and held it in 2 quarters. The position peaked at $1.04M in Q3 2023. 133 funds tracked by Wall St. Rank hold ALPN as of Q4 2023.

  • Steve Schonfeld reported no remaining Alpine Immune Sciences Inc position as of Q4 2023 after selling out during the quarter.
  • Steve Schonfeld sold 90,937 Alpine Immune Sciences Inc shares in Q4 2023, an estimated $1.04M.
  • Steve Schonfeld first reported a position in Alpine Immune Sciences Inc in Q2 2023 and held it in 2 quarters.
  • Steve Schonfeld's Alpine Immune Sciences Inc position peaked at $1.04M in Q3 2023.
  • 133 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q4 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.